“Issuance of the new patent for our oncology preclinical aPKCi inhibitor pipeline is an important part of our development strategy,” said Jed Latkin, CEO of Windtree Therapeutics. “We will continue ...

Windtree Therapeutics (WINT) announced the issuance of a patent in Japan for “Inhibitors of atypical protein kinase C and their use in treating ...

The clinical success of some of these programs has created much interest in protein kinase inhibitors in almost all pharmaceutical companies. Looking back on the development of imatinib ...

Deciphera Pharmaceuticals LLC has patented new serine/threonine-protein kinase B-raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1; c-Raf) inhibitors reported to be useful for ...

Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative ...

Cip/Kip proteins that inhibit cyclin-dependent kinase 2 (Cdk2) restrain the initiation of DNA replication. Degradation of a Xenopus Kip1 orthologue, Xic1, is dependent on its recruitment to ...